Skip to main content
SpringerLink
Log in

Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature

  • Chapter
  • First Online:
ADME Processes in Pharmaceutical Sciences

Abstract

The most relevant pharmacokinetic mechanisms of drug-drug (DD) and food-drug (FD) interactions are summarized from a perspective that will allow the readers to apply the concepts exposed here to other cases referred in the literature or coming from their own clinical experience. The aim of studying DD and FD interactions is to prevent, or to manage, eventual adverse events that can appear during drug treatments. Pharmacological activity depends on adequate drug levels at the action site, but access to these sites for pharmacokinetic sampling is often limited. Thus, we often rely on plasma concentrations as surrogates in efforts to understand exposure-response relationships. However, pharmacokinetic interactions may be hidden or imperceptible. Sometimes, drug concentration in plasma remains unaltered, but it could have changed at the action sites. The new paradigm should now be that the concentration of either the drug, or its metabolite, or any endogenous molecule at the action sites, is always responsible for the clinical effect. Then, pharmacokinetic interaction should be dealt with a wider perspective, not just focusing the research on the administered substance but on the entire environment conditioning the action.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aguado JM, Torre-Cisneros J, Fortún J et al (2009) Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 48:1276–1284

    Article  PubMed  Google Scholar 

  • Akhlaghi F, Trull AK (2002) Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 41:615–637

    Article  CAS  PubMed  Google Scholar 

  • Alvariza S, Ibarra M, Vázquez M et al (2014) Different oral phenytoin administration regimens could modify its chronic exposure and its saliva/plasma concentration ratio. J Med Pharm Innov 1:35–43

    CAS  Google Scholar 

  • Amidon G, Lennernäs H, Shah V et al (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420

    Article  CAS  PubMed  Google Scholar 

  • Amundsen R, Åsberg A, Ohm IK et al (2012) Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos 40:655–661

    Article  CAS  PubMed  Google Scholar 

  • Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:367–378

    Article  CAS  PubMed  Google Scholar 

  • Beckett AH, Rowland M (1965) Urinary excretion kinetics of methylamphetamine in man. J Pharm Pharmacol 17:109–114

    Article  Google Scholar 

  • Bertz R, Hsu A, Lam W et al (2000) Pharmacokinetic interactions between Kaletra (lopinavir/ritonavir or ABT-378/r) and other non-HIV drugs. Fifth international congress on drug therapy in HIV infection. Abstract P291, Poster 438. Glasgow (UK), 22–26 Oct 2000

    Google Scholar 

  • Boffito M, Dickinson L, Hill A et al (2004) Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 37:1376–1384

    Article  CAS  PubMed  Google Scholar 

  • Bowdle TA, Levy RH, Cutler RE (1979) Effect of carbamazepine on valproic acid clearance in normal man. Clin Pharmacol Ther 26:629–634

    Article  CAS  PubMed  Google Scholar 

  • Budha NR, Frymoyer A, Smelick GS et al (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203–213

    Article  CAS  PubMed  Google Scholar 

  • Burger DM, Hugen PW, Kroon FP et al (1998) Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 12:2080–2082

    Google Scholar 

  • Canafax DM, Graves NM, Hilligoss DM et al (1991) Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51:1014–1018

    Article  CAS  PubMed  Google Scholar 

  • Carr RB, Shrewsbury K (2007) Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry 164:1020–1027

    Article  PubMed  Google Scholar 

  • Center for Drug Evaluation and Research. Food and Drug Administration (2002) Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. http://www.fda.gov/cder/guidance/index.htm

  • Chen J, Raymond K (2006) Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 5:3

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cohen K, Meintjes G (2010) Management of individuals requiring ART and TB treatment. Curr Opin HIV AIDS 5:61–69

    Article  PubMed  PubMed Central  Google Scholar 

  • Corley DA (2009) Proton pump inhibitor, H2 antagonists, and risk of hip fracture: a large population-based study [abstract]. Gastroenterology 136:A70

    Article  Google Scholar 

  • Custodio JM, Wu CY, Benet LZ (2008) Predicting drug disposition, absorption / elimination / transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717–733

    Article  CAS  PubMed  Google Scholar 

  • Daneshmend TK (1982) Ketoconazole-cyclosporin interaction. Lancet 2:1342–1343

    Article  CAS  PubMed  Google Scholar 

  • Datz F, Christian P, Moore J (1987) Gender-related differences in gastric emptying. J Nucl Med 28:1204–1207

    CAS  PubMed  Google Scholar 

  • Doig MV, Clare RA (1991) Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr 554:181–189

    Article  CAS  PubMed  Google Scholar 

  • Eiraldi R (1997) Interactions on digoxin. Dissertation for doctor in chemistry thesis, Universidad de la República (Uruguay)

    Google Scholar 

  • Eiraldi R, Sánchez S, Olano I et al (2004) Study of drug interactions of Cyclosporine A in two renal transplant patients. Revista O.F.I.L. 14:13–23

    Google Scholar 

  • European Medicines Agency (EMA) (2012) Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev. 1 Corr. 2**

    Google Scholar 

  • Eytan GD, Regev R, Oren G et al (1996) The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 271:12897–12902

    Article  CAS  PubMed  Google Scholar 

  • Fagiolino P (2004) Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence. Eur J Drug Metab Pharmacokinet 29:43–49

    Article  CAS  PubMed  Google Scholar 

  • Fagiolino P, Vázquez M, Eiraldi R et al (2011) Efflux transporter influence on drug metabolism: theoretical approach for bioavailability and clearance prediction. Clin Pharmacokinet 50:75–80

    Article  PubMed  Google Scholar 

  • Fagiolino P, Vázquez M, Alvariza S et al (2014) Antiepileptic drugs: energy-consuming processes governing drug disposition. Front Biosci (Elite Ed) E6:387–396

    Article  CAS  Google Scholar 

  • Fan-Havard P, Liu Z, Chou M et al (2013) Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother 57:2154–2160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Faught E, Morris G, Jacobson M et al (1999) Adding lamotrigine to valproate: incidence of rash and other adverse effects. Epilepsia 40:1135–1140

    Article  CAS  PubMed  Google Scholar 

  • Fang AF, Damle BD, LaBadie RR et al (2008) Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy 28:42–50

    Google Scholar 

  • Ferguson RM, Sutherland DE, Simmons RL et al (1982) Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 2:882–883

    Article  CAS  PubMed  Google Scholar 

  • Ferte J (2000) Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267:277–294

    Article  CAS  PubMed  Google Scholar 

  • Fitton A, Goa KL (1995) Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691–713

    Article  CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2013) FDA [7-26-2013]. Available on https://www.fda.gov/Drugs/DrugSafety/ucm362415.htm

  • Freeman DJ (1991) Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem 24:9–14

    Article  CAS  PubMed  Google Scholar 

  • Fricker G, Drewe J, Huwyler J et al (1996) Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro–in vivo correlation. Br J Pharmacol 118:1841–1847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Funakoshi S, Murakami T, Yumoto R et al (2005) Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci 94:1196–1203

    Article  CAS  PubMed  Google Scholar 

  • Ghodke-Puranik Y, Thorn CF, Lamba JK et al (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23:236–241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greiner B, Eichelbaum M, Fritz P et al (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gugler R, von Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5:67–83

    Article  CAS  PubMed  Google Scholar 

  • Hamer JHM, Knake S, Schomburg U et al (2000) Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54:230–232

    Article  CAS  PubMed  Google Scholar 

  • Hirsh J, Fuster V, Ansell J et al (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107(12):1692–1711

    Article  PubMed  Google Scholar 

  • Hosagrahara V, Reddy J, Ganguly S et al (2013) Effect of repeated dosing on rifampin exposure in BALB/c mice. Eur J Pharm Sci 49:33–38

    Article  CAS  PubMed  Google Scholar 

  • Ibarra M, Fagiolino P, Vázquez M et al (2012) Impact of food administration on lopinavir-ritonavir bioequivalence studies. Eur J Pharm Sci 46:516–521

    Article  CAS  PubMed  Google Scholar 

  • Ibarra M, Vázquez M, Fagiolino P (2014) Population pharmacokinetic model to analyze nevirapine multiple-peaks after a single oral dose. J Pharmacokinet Pharmacodyn 41:363–373

    Article  CAS  PubMed  Google Scholar 

  • Ibarra M, Magallanes L, Lorier M et al (2016) Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Eur J Pharm Sci 85:106–111

    Article  CAS  PubMed  Google Scholar 

  • Ibarra M, Vázquez M, Fagiolino P (2017) Sex effect on average bioequivalence. Clin Ther 39:23–33

    Article  CAS  PubMed  Google Scholar 

  • Ito T, Jensen RT (2010) Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 12:448–457

    Article  PubMed  PubMed Central  Google Scholar 

  • Jawhari D, Alswisi M, Ghannam M et al (2014) Bioequivalence of a new generic formulation of erlotinib hydrochloride 150 mg tablets versus tarceva in healthy volunteers under fasting conditions. J Bioequiv Availab 6:119–123

    Article  CAS  Google Scholar 

  • Jensen RT (2006) Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98:4–19

    Article  CAS  PubMed  Google Scholar 

  • Johnson MD, Hamilton CD, Drew RH et al (2003) A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 51:453–457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keam SJ (2008) Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. BioDrugs 22:59–69

    Article  CAS  PubMed  Google Scholar 

  • Kenyon CJ, Hooper G, Tierney D et al (1995) The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. J Control Release 34:31–36

    Article  CAS  Google Scholar 

  • Kerr BM, Rettie AE, Eddy AC et al (1989) Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 46:82–93

    Article  CAS  PubMed  Google Scholar 

  • Kim RB, Fromm MF, Wandel C et al (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kodawara T, Masuda S, Wakasugi H et al (2002) Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 19:738–743

    Article  CAS  PubMed  Google Scholar 

  • Koop H, Bachem MG (1992) Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 14:288–292

    Article  CAS  PubMed  Google Scholar 

  • La Porte CJ, Colbers EP, Bertz R et al (2004) Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48:1553–1560

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lalic M, Cvejic J, Popovic J et al (2009) Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 34:93–99

    Article  CAS  PubMed  Google Scholar 

  • Lambert C, Lamontagne D, Hottlet H et al (1989) Amiodarone-digoxin interaction in rats. A reduction in hepatic uptake. Drug Metab Dispos 17:704–708

    CAS  PubMed  Google Scholar 

  • Leather H, Boyette RM, Tian L et al (2006) Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12:325–334

    Article  CAS  PubMed  Google Scholar 

  • Lennard-Jones JE, Fletcher J, Shaw DG (1968) Effect of different foods on the acidity of the gastric contents in patients with duodenal ulcer. Part III: effect of altering the proportions of protein and carbohydrate. Gut 9:177–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lheureux PER, Penaloza A, Zahir S et al (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence? Crit Care 9:431–440

    Article  PubMed  PubMed Central  Google Scholar 

  • Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31–59

    Article  CAS  PubMed  Google Scholar 

  • Lown KS, Mayo RR, Leichtman AB et al (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248–260

    Article  CAS  PubMed  Google Scholar 

  • Lu W, Uetrecht JP (2007) Possible bioactivation pathways of lamotrigine. Drug Metab Dispos 35:1050–1056

    Article  CAS  PubMed  Google Scholar 

  • Magallanes L, Lorier M, Ibarra M et al (2016) Sex and food influence on intestinal absorption of ketoprofen gastroresistant formulation. Clin Pharmacol Drug Dev 5:196–200

    Article  CAS  PubMed  Google Scholar 

  • Maggs JL, Naisbitt DJ, Tettey JNA et al (2000) Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 13:1075–1081

    Article  CAS  PubMed  Google Scholar 

  • Mahatthanatrakul W, Nontaput T, Ridtitid W et al (2007) Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 32:161–167

    Article  CAS  PubMed  Google Scholar 

  • Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147–169

    Article  CAS  PubMed  Google Scholar 

  • Maldonado C, Fagiolino P, Vázquez M et al (2011) Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring. Lat Am J Pharm 30:908–912

    CAS  Google Scholar 

  • Maldonado C, de Mello N, Fagiolino P et al (2015) Safe use of a daily 20-mg dose of omeprazole in order to avoid hypomagnesemia. Int J Pharm 5:315–321

    CAS  Google Scholar 

  • Maldonado C, Guevara N, Queijo C et al (2016) Carnitine and/or acetylcarnitine deficiency as a cause of higher levels of ammonia. Biomed Res 2016:2920108

    Google Scholar 

  • Maldonado C, Guevara N, Silveira A et al (2017) L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: a case report. J Int Med Res 45:1268–1272

    Article  PubMed  PubMed Central  Google Scholar 

  • Mehndiratta MM, Mehndiratta P, Phul P et al (2008) Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)-a study from tertiary care referral university hospital, North India. J Pak Med Assoc 58:627–631

    PubMed  Google Scholar 

  • Melander A (1978) Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3:337–351

    Article  CAS  PubMed  Google Scholar 

  • Michalek W, Semler JR, Kuo B (2011) Impact of acid suppression on upper gastrointestinal pH and motility. Dig Dis Sci 56:1735–1742

    Article  CAS  PubMed  Google Scholar 

  • Miret S, Simpson RJ, McKie AT (2003) Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr 23:283–301

    Article  CAS  PubMed  Google Scholar 

  • Mizunashi K, Furukawa Y, Katano K et al (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25

    Article  CAS  PubMed  Google Scholar 

  • Moayyedi P, Cranney A (2008) Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol 103:2428–2431

    Article  CAS  PubMed  Google Scholar 

  • Mueller EA, Kovarik JM, van Bree JB et al (1994) Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 11:151–155

    Article  CAS  PubMed  Google Scholar 

  • Mugabo P, Els I, Smith J et al (2011) Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J 101:655–658

    CAS  PubMed  Google Scholar 

  • Myers Davit B, Conner D (2008) Food effects on drug bioavailability: implications for new and generic drug development. In: Krishna R, Yu L (eds) Biopharmaceutics applications in drug development, vol 21. Springer US, Boston, pp 317–335

    Chapter  Google Scholar 

  • Naisbitt DJ (2004) Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194:179–196

    Article  CAS  PubMed  Google Scholar 

  • Naylor H, Robichaud J (2013) Decreased tacrolimus levels after administration of rifampin to a patient with renal transplant. Can J Hosp Pharm 66:388–392

    PubMed  PubMed Central  Google Scholar 

  • Nijland HM, L’Homme RF, Rongen GA et al (2008) High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 22:931–935

    Article  CAS  PubMed  Google Scholar 

  • Osowski CL, Dix SP, Lin LS et al (1996) Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 61:1268–1272

    Article  CAS  PubMed  Google Scholar 

  • Palleria C, Di Paolo A, Giofrè C et al (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18:601–610

    PubMed  PubMed Central  Google Scholar 

  • Perazella MA (2013) Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 83:553–556

    Article  CAS  PubMed  Google Scholar 

  • Ramachandran G, Hemanth Kumar AK, Rajasekaran S et al (2009) CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 53:863–868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ramanathan S, Mathias AA, German P et al (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50:229–244

    Article  CAS  PubMed  Google Scholar 

  • Reece PA, Kotasek D, Morris RG et al (1986) The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 16:194–197

    Article  CAS  PubMed  Google Scholar 

  • Riska P, Lamson M, MacGregor T et al (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895–901

    CAS  PubMed  Google Scholar 

  • Romero AJ, Le Pogamp P, Nilsson LG et al (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71:226–234

    Article  CAS  PubMed  Google Scholar 

  • Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roux C, Briot K, Gossec L et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13–19

    Article  CAS  PubMed  Google Scholar 

  • Saeki T, Ueda K, Tanigawara Y et al (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077–6080

    CAS  PubMed  Google Scholar 

  • Schachter M (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–125

    Article  CAS  Google Scholar 

  • Schlienger RG, Knowles SR, Shear NH (1998) Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 51:1172–1175

    Article  CAS  PubMed  Google Scholar 

  • Schmidt LE, Dalhoff K (2002) Food-drug interactions. Drugs 62:1481–1502

    Article  CAS  PubMed  Google Scholar 

  • Sharma VR, Brannon MA, Carloss EA (2004) Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 97:887–889

    Article  PubMed  Google Scholar 

  • Sibl A, Hrudikova-Vyskocilova E, Kacirova I et al (2017) Pharmacokinetic interaction between digoxin and amiodarone. Clin Ther 39:e82

    Article  Google Scholar 

  • Siemes H, Nau H, Schultze K et al (1993) Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 34:332–346

    Article  CAS  PubMed  Google Scholar 

  • Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213–255

    Article  CAS  PubMed  Google Scholar 

  • Steinberg M (2007) Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic. Clin Ther 29:2289–2308

    Article  CAS  PubMed  Google Scholar 

  • Stewart CA, Termanini B, Sutliff VE et al (1998) Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12:83–98

    Article  CAS  PubMed  Google Scholar 

  • Sutton SC, Nause R, Gandelman K (2017) The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. AAPS J 19:1084–1090

    Article  CAS  PubMed  Google Scholar 

  • Takada T, Yamanashi Y, Konishi K et al (2015) NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. Sci Transl Med 7:275ra23

    Article  CAS  PubMed  Google Scholar 

  • Usach I, Melis V, Peris JE (2013) Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc 16:1–14

    Article  PubMed  Google Scholar 

  • Valk-Swinkels CG, Alidjan F, Rommers MK et al (2013) Low cyclosporin levels induced by the brief use of rifampicin; immunosuppression may fail for several weeks. Ned Tijdschr Geneeskd 157:A5667

    PubMed  Google Scholar 

  • Vázquez M, Fagiolino P, Mariño EL (2013) Concentration-dependent mechanisms of adverse drug reactions in epilepsy. Curr Pharm Des 19:6802–6808

    Article  PubMed  CAS  Google Scholar 

  • Vázquez M, Fagiolino P, Maldonado C et al (2014) Hyperammonemia associated with valproic acid concentrations. Biomed Res Int 2014:217–269

    Article  CAS  Google Scholar 

  • Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83

    Article  CAS  PubMed  Google Scholar 

  • Vourvahis M, Kashuba AD (2007) Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27:888–909

    Article  CAS  PubMed  Google Scholar 

  • Wang E, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 46:160–165

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warner NJ, Barnard JT, Bigger JT (1985) Tissue digoxin concentrations and digoxin effect during the quinidine-digoxin interaction. J Am Coll Cardiol 5:680–686

    Article  CAS  PubMed  Google Scholar 

  • Wessler JD, Grip LT, Mendell J et al (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61:2495–2502

    Article  CAS  PubMed  Google Scholar 

  • Williams L, Davis JA, Lowenthal DT (1993) The influence of food on the absorption and metabolism of drugs. Med Clin North Am 77:815–829

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization (2012) WHO policy on collaborative TB/HIV activities – guidelines for national programmes and other stakeholders. ISBN: 9789241503006

    Google Scholar 

  • Wright MJ, Sullivan RR, Gaffney-Stomberg E et al (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young healthy individuals: a randomized, crossover controlled clinical trial. J Bone Miner Res 25:2205–2211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23

    Article  CAS  PubMed  Google Scholar 

  • Wu KL, Chaikomin R, Doran S et al (2006) Artificially sweetened versus regular mixers increase gastric emptying and alcohol absorption. Am J Med 119:802–804

    Article  CAS  PubMed  Google Scholar 

  • Xue L, Holford N, Ding X-L et al (2017) Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. Br J Clin Pharmacol 83:823–835

    Article  CAS  PubMed  Google Scholar 

  • Yamashita F, Sasa Y, Yoshida S et al (2013) Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro. PLoS One 8:e70330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang KM, Shin IC, Park JW et al (2017) Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm 43:1557–1565

    Article  CAS  PubMed  Google Scholar 

  • Yang YX, Lewis JD, Epstein S et al (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 296:2947–2953

    Article  CAS  Google Scholar 

  • Yuen AWC, Land G, Weatherley BC et al (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33:511–513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zielinski JJ, Haidukewych D (1987) Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 9:21–23

    Article  CAS  PubMed  Google Scholar 

  • Zielinski JJ, Haidukewych D, BJn L (1985) Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit 7:51–53

    Article  CAS  PubMed  Google Scholar 

  • Zhu L, Persson A, Mahnke L et al (2011) Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol 51: 368-377

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Sciences Department, Faculty of Chemistry, Universidad de La República, Montevideo, Uruguay

    Pietro Fagiolino, Marta Vázquez, Manuel Ibarra, Cecilia Maldonado & Rosa Eiraldi

Authors
  1. Pietro Fagiolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manuel Ibarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cecilia Maldonado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosa Eiraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pietro Fagiolino .

Editor information

Editors and Affiliations

  1. Laboratory of Bioactive Research and Development (LIDeB), Department of Biological Sciences, Faculty of Exact Sciences, University of La Plata (UNLP), La Plata, Buenos Aires, Argentina

    Alan Talevi

  2. Quality Control of Pharmaceutical Products, Pharmaceutical Toxicology, Department of Biological Sciences, Faculty of Exact Sciences, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina

    Pablo A. M. Quiroga

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fagiolino, P., Vázquez, M., Ibarra, M., Maldonado, C., Eiraldi, R. (2018). Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature. In: Talevi, A., Quiroga, P. (eds) ADME Processes in Pharmaceutical Sciences. Springer, Cham. https://doi.org/10.1007/978-3-319-99593-9_12

Download citation

Publish with us

Policies and ethics

Search

Navigation